Pharma Update

Neoantigen vaccine: Autogene cevumeran <+ Cancer Center Memorial Sloan Kettering BIONTECH Roche 1884 Substantially and durably expanded T-cells, correlating with delayed recurrence Phase I results in surgically resectable PDAC (target n=20) ASCO® 2022 Vaccine induced T-cell response associated with longer RFS Tumor and normal DNA N Resection Tumor RNA Neoantigen prediction mRNA manufacture Custom manufacture neoantigen mRNA vaccine Week: 0 6 9 I Dose/cycle: 1 Screen for eligibility Surgery Atezolizumab 1 dose Administer vaccine 17 21 1 2 3 4 5 6 8 Individualized neoantigen vaccine Doses 1-8 mFOLFIRINOX 12 cycles RFS (%) 100 Median RFS: Not reached T 50 50 46 Follow-up Median RFS: 13.7 months 10 11 12 9 0 Individualized neoantigen vaccine Dose 9 06 12 18 T 24 1 30 Months Median follow-up: 18 months Responder (n=8) Non-responder (n=8) P = 0.003 HR: 0.08 (95% CI 0.01-0.40) Autogene cevumeran expanded polyclonal IFNy-producing neoantigen-specific CD8 + T-cells in 50% (n = 8/16) of patients from undetectable levels to large fractions (median 2.9%) of all blood T-cells Randomized trial in PDAC initiated, FPI expected Q3 2023 Planning to initiate additional studies in other tumors Autogene cevumeran in partnership with BioNtech; Balachandran V et al., ASCO 2022; PDAC-pancreatic ductal adenocarcinoma; RFS-relapse free survival 80

View entire presentation